This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bloom, D. A. Search for Related Content PubMed Articles by Bloom, D. A. Social Bookmarking                         What's this?

The American Experience With Desmopressin

Pediatric Urology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0330

Conclusive evidence of a polyuric etiology from a failure of vasopressin elevation led to a new pharmacologic approach to the treatment of childhood nocturnal enuresis. Desmopressin acetate, a vasopressin analogue, has been used successfully since 1978 to treat this condition. Desmopressin's efficacy at doses of 5 to 40 µg has been demonstrated in Europe and the United States. Similarly, its safety has been established, and it is a first-line choice for physicians worldwide.

Clinical Pediatrics, Vol. 32, No. 1 suppl, 28-31 (1993)
DOI: 10.1177/000992289303200107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?